erlotinib hydrochloride has been researched along with cyclin d1 in 14 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Bee, T; Black, CC; Dmitrovsky, E; Ewings, KE; Freemantle, SJ; Hattab, EM; Kelley, MR; Krizan, KA; Memoli, VA; Spinella, MJ; Vaseva, AV | 1 |
| Garber, K | 1 |
| Andrew, AS; Duell, EJ; Mason, RA; Memoli, V | 1 |
| Chung, WC; Gold, KA; Hittelman, WN; Kang, SM; Ki Hong, W; Kim, ES; Koo, JS; Lee, J; Ryu, SH | 1 |
| Dragnev, KH; Graham, RM; Memoli, VA; Petty, WJ; Swift, CB; Urbanic, JJ; Varela, VA; Voelzke, WR; Waller, LL | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Bhatnagar, PK; Dastidar, SG; Kapoor, S; Nithya, D; Ray, A; Senthil, V; Sharma, A; Talwadkar, A; Tandon, R; Vali, S; Venkataramanan, R | 1 |
| Arcaroli, J; Cusatis, G; Garrett-Mayer, E; Hidalgo, M; Messersmith, WA; Rubio-Viqueira, B; Song, D; Weekes, CD; Wilson, LA; Winn, RA | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X | 1 |
| Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A | 1 |
| Chen, D; Chen, S; Haisma, H; Liu, B; Saber, A | 1 |
3 trial(s) available for erlotinib hydrochloride and cyclin d1
| Article | Year |
|---|---|
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
11 other study(ies) available for erlotinib hydrochloride and cyclin d1
| Article | Year |
|---|---|
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Topics: Biomarkers, Tumor; Bronchi; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclin D1; DNA; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Exons; G1 Phase; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Kinetics; Luciferases; Necrosis; Neoplasms; Quinazolines; Sequence Analysis, DNA; Time Factors; Transcriptional Activation | 2004 |
Repression of cyclin D1 as a target for germ cell tumors.
Topics: Antineoplastic Agents; Cell Differentiation; Cyclin D1; DNA Fragmentation; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Germ Cell and Embryonal; Quinazolines; Receptors, Retinoic Acid; RNA, Heterogeneous Nuclear; RNA, Small Interfering; Time Factors; Tretinoin | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Arsenic activates EGFR pathway signaling in the lung.
Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds | 2009 |
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Topics: Bronchi; Butadienes; Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hyperplasia; Luciferases; Lung Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Nitriles; Organ Culture Techniques; Quinazolines; RNA, Small Interfering | 2011 |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
Topics: Animals; Biomarkers, Pharmacological; Carcinoma; Cyclin D1; Cyclin D3; Cyclin E; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Quinazolines | 2011 |
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Computational Biology; Cyclin D1; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1 | 2011 |
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Quinazolines; Receptors, CXCR; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2012 |
Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid | 2015 |
Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Survival Analysis; Transcriptional Activation | 2020 |